Enzolytics Inc (OTCMKTS: ENZC) is making a powerful move up the charts in recent days since reversing off $0.06 support levels, the second time it has tested the $0.06 over the past month. ENZC is a major league runner and powerhouse stock and was among the biggest runners of spring 2021 making a legendary run to highs of 0.958 per share as it completed the historic merger between BioClonetics and Enzolytics; the new biotech is getting noticed as its technology for producing fully human monoclonal antibodies is currently being employed to produce anti-SARS-CoV-2 (CoronaVirus) monoclonal antibodies for treating COVID-19 and HIV. ENZC is one of the top most traded stocks on the OTCBB and has some of its biggest players behind it looking for another legendary breakout from current levels.
Dr. Gaurav Chandra of ENZC recently joined the Stock Day Podcast to discuss the biotech’s revenue potential among others things. Dr. Chandra made some important points stating “While we have already launched IPF Immune™ in the United States, we are also launching the product in Europe and Canada in the next three months.” IPF Immune™ has shown positive results during testing against the CoronaVirus (SARS-CoV-2) strain 229e as well as Adenovirus another booming market. The Company’s monoclonal antibody program is progressing rapidly: “We have identified the conserved immutable targets in about 20 viruses” said. Dr. Chandra, “and then we went a bit further. We built AI-based three-dimensional models of these immutable targets and established linearity, neutralization by antibodies or accessibility by antibodies, before moving forward to develop monoclonal antibodies that target these specific sequences. We actually did the same thing for HIV viruses. We identified 8 conserved immutable targets. The virus can mutate many times, but since these are conserved it will remain unchanged. The resulting monoclonal antibodies that we have created are universal, durable, broadly utilizing, and will remain unaffected by mutations or virus escape.” Dr. Chandra. also discussed the global monoclonal antibody market worth $144 billion. “We have four monoclonal antibodies for infectious diseases that are in clinical development as we speak.” said Dr. Chandra. “As you can imagine, although the market is not reflecting the actual market cap of the company, in the next six months to one year we anticipate a monumental shift in the position of the company as our clinical products start coming to the market.”
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Enzolytics, Inc. is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. ENZC has been rapidly building up an intellectual property portfolio filing numerous patents last year. Most recently, last month, the Company reported it has received the official filing receipt from the U.S. Patent Office confirming the filing of its patent application for “Nuclear Proteins Isolated from Mammalian Spinal Cord Immune Factor – Pharmaceutical Composition for Treatment.” Since than the ENZC has filed a number of new applications. The Company recently merged with BioClonetics Immunotherapeutics, Inc., now a wholly owned subsidiary of Enzolytics; a Dallas and College Station, Texas biotech company with proprietary technology for producing fully human monoclonal antibodies (mAbs) against infectious diseases.
Microcapdaily has been reporting on the ENZC BioColnetics merger since the beginning first when it was $0.003 recenlty stating: “Enzolytics Inc (OTCMKTS: ENZC) is making an explosive move up the charts after the Company announced a progress update and more on its future plans. The Company spoke in depth of its work at Texas A&M University Institute for Preclinical Studies focused on the production of fully human monoclonal antibodies targeting multiple infectious diseases, including SARS-CoV-2 and HIV-1. Management also outlined the Company’s development of Artificial Intelligence for use in in-vitro diagnostic tests that diagnose viral diseases based on the presence of the conserved sites that remain unaffected by mutations. At Enzolytics’s Dallas laboratory, managed by Harry Zhabilov, the Company’s CSO who coordinates the development and the production of two of the Company’s primary therapeutics, ITV-1 and IPF Immune. Both therapeutics are produced under patents invented by Mr. Zhabilov, U.S. Patent Nos. 8,066,982, 7,479,538, and 8,309,072. ITV-1 is a therapeutic for treating individuals with HIV. It has been successfully produced and has been earlier successfully clinically tested in human trials under the Bulgarian Drug Agency requirements. The Company has also completed the production of IPF Immune, a product shown to function effectively as an immune booster.
ENZC IPF Immune therapeutic is now entering the U.S. market. This science-backed immune modulator helps strengthen the body’s defenses against viruses or other pathogens. The product works as an immune booster that increases the ability of the immune system to fight infections by stimulating antiviral activity and helping to increase cell defense. The product supports the body’s immune system thereby enhancing recovery and reducing the recovery period after an illness. The Company is also planning to launch IFP Immune in Europe and Canada. The Company has distributorship contacts in Europe and sees tremendous added potential from foreign sales. This product enters the market as sales of American Dietary Supplements in North American reach $50.11 Billion. These sales are forecast to increase to $77.10 Billion in 2028. Enzolytics has engaged Nutritional Products International (NPI) to access this 50-billion-dollar market=Enzolytics IPF Immune will meet consumer needs due to its significant benefits.
— Stock Day Media (@StockDayPodcast) May 16, 2022
To Find out the inside Scoop on ENZC Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
Dr. Chandra continued on the Stock Day Podcast then discussing the importance of AI-driven diagnostics. “We are discussing partnerships with diagnostic companies that have a track record of getting diagnostics tests through Regulatory approval and distributing these diagnostic tests for clinical use. As viruses mutate, the diagnostic test for them have to be modified to identify each mutant of the virus. But since the targets we have identified remain unchanged, if those target sites are used to diagnose the virus, then you have a test that is universally applicable even for mutants of the viruses.”
Talking about AI-driven prognostics he said that there are documented studies showing better prognosis and clinical outcomes in patients with antibodies to the AI-identified conserved targets. Enzolytics is also discussing a potential partnership to develop a prognostic test that predicts immune response before receiving a vaccine or antiviral therapy.
“Since we have the capability of identifying conserved targets, we are actually working to be a part of consortiums that are looking to prevent the next global pandemic, and that is very exciting for us. The AI platform significantly cuts down the time for our drug discovery and development. At Enzolytics, we build a product and put effort into R&D, and then we intend to partner with a larger entity, a large pharmaceutical company, that can take it through the clinical stages quickly.
Dr. Chandra noted the significant market for each of the Company’s products. “The next product that we have is ITV-1, which is an HIV therapeutic and has actually cleared Phase III clinical trials and is preparing for introduction into two markets,” he explained. “The African market is a significant market because 65% of about 34 to 37 million HIV infected individuals live in Africa. We will also be introducing this product into Europe, and are currently awaiting certification under the European Medical Agency.”
— Samath Moeung (@MoeungSamath) May 16, 2022
For more on ENZC Subscribe Right Now!
ENZC is making a powerful move up the charts in recent days since reversing off $0.06 support levels, the second time it has tested the $0.06 over the past month. ENZC is a major league runner and powerhouse stock and was among the biggest runners of spring 2021 making a legendary run to highs of 0.958 per share as it completed the historic merger between BioClonetics and Enzolytics; the new biotech is getting noticed as its technology for producing fully human monoclonal antibodies currently being employed to produce anti-SARS-CoV-2 (CoronaVirus) monoclonal antibodies for treating COVID-19 and HIV. ENZC could become a major player in the enormous $30 billion annual HIV market expected to reach $37 billion in the next 5 years. In a market primarily controlled by Gilead who sold $17 billion in HIV drugs last year Enzolytic’s HIV treatment is immunotherapy, not chemotherapy. One of the things that makes Enzolytic’s ITV-1 stand out from the pack is its safety profile. ITV-1 is really a form of immunotherapy that strengthens the immune system. ENZC has real potential here, it’s a biotech right at 52 week lows, has one of the biggest audiences on the OTCQB, recent highs near $1 and is seeing significant progress with multiple upcoming catalysts in play. Microcapdaily first reported on ENZC on September 16 just as it was taking off after closing at $0.0009 the day before. We will be updating on ENZC when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with ENZC.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: we hold no position in ENZC either long or short and we have not been compensated for this article.